AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

Home
/
update
/
details

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

NextEdge Admin

21 Dec 2024

2 min 53 sec

CAR-T cell therapy,multiple myeloma,research

Doctors at AIIMS, Delhi, are working on a low-cost antibody-based adaptive cellular therapy to treat multiple myeloma, a type of blood cancer. This initiative aims to make advanced treatments like CAR-T cell therapy more affordable and accessible in India.

CAR-T cell therapy involves isolating a patient’s T cells, genetically modifying them to target cancer cells, and re-infusing them into the body. The therapy being developed by AIIMS targets B-cell maturation antigen (BCMA), a tumor-specific marker in multiple myeloma, enabling the modified cells to recognize and destroy cancer cells. Dr. Mayank Singh, Additional Professor of Medical Oncology at BRAIRCH, stated that their therapy has shown promising results in animal models, and phase-1 clinical trials on humans are planned to evaluate its safety and efficacy.

Multiple myeloma originates in plasma cells, a type of white blood cell that produces antibodies. When these cells become cancerous, they multiply rapidly, overcrowding healthy cells in the bone marrow and often leading to relapses. Traditional treatments like chemotherapy and radiotherapy indiscriminately target rapidly dividing cells, causing severe side effects. Although targeted therapies and immunotherapies, such as monoclonal antibodies, have improved outcomes, their high costs make them inaccessible for many patients in India.

AIIMS researchers have patented an antibody for this therapy and are filing a patent for their CAR-T cell approach. The therapy integrates antibody components to target cancer antigens specifically, improving efficacy while reducing off-target effects. The team’s objective is to drastically lower the cost, addressing India’s cancer burden, where one in nine individuals is likely to develop cancer during their lifetime.

With over 14.6 lakh new cancer cases in India in 2022, affordable CAR-T cell therapy could transform cancer care, providing hope to millions by bridging the gap between advanced treatments and accessibility.